In mice with experimental immune cardiogenic shock, intravenous infusion of dalargin, delta-sleep peptide, levamisole and T-activon was reported together as decreasing life span and/or increasing mortality.
In plain wordsIn mice with shock, a group of drugs that included delta-sleep peptide shortened life span or raised deaths. No result per drug.
- Outcome
- MixedLife span and mortality with intravenous infusion
- Study
mousen: not reported in source
immune cardiogenic shock- Outcome group
- Mortality · Cardiovascular
Source sentences
Dalargin, delta-sleep peptide, levamisole, and T-activon decreased mice's life span and/or increased their mortality when the mice were given intravenous infusions of these agents.
1 context sentence(design, population, supporting numbers)
The efficacy of dalargin, delta-sleep peptide, finoptin, levamisole, and prednisolone was studied in 104 white mice with experimental immune cardiogenic shock.
In this study, Delta sleep-inducing peptide (DSIP) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Delta sleep-inducing peptide (DSIP).